NCT01347047Completed
HIBA-Institutional Registry of Amyloidosis
Institutional Registry of Amyloidosis (Hospital Italiano de Buenos Aires)
Source: ClinicalTrials.gov · Last updated 21 Jul 2026
Brief summary (registry, in English)
1. Creating a population-based registry system Amyloidosis prospective epidemiological survey * risk factors * diagnosis * prognosis * treatment * monitoring * survival 2. Describe the occurrence of amyloidosis in the population of HIBA, Hospital Italiano de Buenos Aires. 3. Describe the characteristics of clinical presentation, evolution and predisposing factors of amyloidosis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 2 May 2011
- Start date
- Apr 2011
- Primary completion date
- Jul 2026
- Lead sponsor
- Hospital Italiano de Buenos Aires
- Diseases
- Amyloidosis
- NCT number
- NCT01347047
What you commit to
- Study type: Observational
- Planned participants: 500
- From Apr 2011 to the primary completion date, Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Cases of amyloidosis are captured by electronic medical records whenever the physician register amyloidosis as a patient diagnosis, and/or there is amyloidosis in a biopsy specimen and/or requests for the following studies of an adult patient: plasma kappa and lambda light-chain concentrations, the kappa: lambda ratio, transthoracic Doppler echocardiography, or cardiovascular magnetic resonance examination or pyrophosphate scintigraphy From the possible cases included in the IRA, a prospective review of the electronics health records was performed to confirm the presence of amyloidosis
- \*\*Inclusion Criteria: 1 AND (2 or 3)
- Patients over 18 years:
- Confirmed amyloidosis: Proof of deposit of amyloid pathology by tissue biopsy in abdominal fat, bone marrow, rectum or organ involved (eg, kidney, liver, sural nerve)
- Clinically compatible case of Amyloidosis :
- Exclusion Criteria:
- Refusal to participate in the study or the informed consent process by the patient or legal representative or refusal to consent to participate in the study in the case of minors.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Italiano de Buenos Aires Coordinator of this site? Confirm its status | Buenos Aires | Argentina | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.